Skip to main content
OpenTrials
Completed

NCT Number: NCT02731638

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

Mycotic Antimicrobial Localized Injection (MALIN) is a randomized, masked, two-arm clinical trial investigating intrastromal voriconazole in the treatment of fungal corneal ulcers. There is currently little evidence to guide the treatment of fungal keratitis beyond topical anti-fungal drops, though intrastromal voriconazole and oral antifungal treatments are used as well. This study will provide evidence to guide the treatment of fungal keratitis in the future. The purpose of this study is to determine differences in microbiological cure for 3-day repeat cultures between different antifungal treatments. For this study, there will be 1:1 randomization to one of these two treatment groups: 1) topical natamycin plus intrastromal voriconazole injection or 2) topical natamycin alone.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Aravind Eye Hospitals, Pondicherry, Tamil Nadu, India

Loading trial locations.

About this study

The proposed study is a randomized controlled trial to determine whether intrastromal voriconazole improves outcomes in fungal keratitis. Patients presenting to the Aravind Eye Hospitals in Pondicherry, India for treatment of fungal keratitis will be recruited for the proposed study. Approximately 70 patients will be enrolled in the study. Subjects presenting with fungal keratitis will be randomized to receive topical natamycin plus intrastromal voriconazole or to receive topical natamycin alone. Subjects may also receive oral antifungals after day 3 at the discretion of the treating clinician. All study subjects will be followed for 3 months to evaluate response to treatment.

Investigators from the University of California, San Francisco (UCSF) will assist Aravind Eye Hospital with the study design, implementation, and analysis of the research, and will help fund the study. The investigators will visit Aravind to help with the study implementation. UCSF will play an important role in this study by assisting with the study design, implementation, analysis, and funding.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Moderate to severe corneal ulcer that is smear positive for filamentous fungus
  • Pinhole visual acuity worse than 20/70 in affected eye
  • Basic understanding of the study as determined by the physician
  • Commitment to return for follow up visits

Exclusion criteria

  • Gram stain positive for bacteria or evidence of other concomitant infection (i.e. herpes, acanthamoeba)
  • Impending or frank perforation at recruitment
  • Involvement of sclera at presentation
  • Non-infectious or autoimmune keratitis
  • History of corneal transplantation or recent intraocular surgery
  • No light perception in the affected eye
  • Pinhole visual acuity worse than 20/200 in the unaffected eye
  • Pregnant women
  • Participants who are decisionally and/or cognitively impaired

Treatment and study plan

Intrastromal voriconazole

Drug

Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.

Natamycin

Drug

Subjects will receive topical 5% natamycin drops hourly for 3 days.

Primary outcomes

  1. Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus

    Time frame: 3 days

    Number of of participants with positive fungal cultures at 3 days

Secondary outcomes

  1. Best Spectacle-corrected Visual Acuity, as Measured by a Refractionist

    Time frame: 3 weeks and 3 months

    Best spectacle-corrected visual acuity using calibrated Original Series Early Treatment Diabetic Retinopathy Study eye charts and recorded as number of letter read.

  2. Scar Size

    Time frame: 3 weeks and 3 months

    Scar size, geometric mean

  3. Number of Participants With Scar Depth at the Anterior Third, Middle Third, and Posterior Third of the Cornea

    Time frame: 3 weeks and 3 months

    Number of participants with scar depth at the anterior third (0-33% depth), middle third (>33-67% depth), and posterior third (>67-100% depth) of the cornea, as measured on slit lamp exam.

Other outcomes

  1. Corneal Neovascularization

    Time frame: 3 months

    As measured by clinical examination and slit lamp photographs.

  2. Change in Quality of Life, Measured by the Indian Vision Function Questionnaire (IND-VFQ)

    Time frame: 3 months

  3. Corneal Thinning, as Measured by Pachymetry and OCT

    Time frame: 6 months

  4. Corneal Topography, as Measured by a Non-contact Imaging Topographer

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Aravind Eye Hospitals, India

Registry information

Acronym: MALIN

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Apr 7, 2016
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.